Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Outcome Preferences in Patients With Noninfectious Uveitis: Results of a Best-Worst Scaling Study.

Yu T, Holbrook JT, Thorne JE, Flynn TN, Van Natta ML, Puhan MA.

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6864-72. doi: 10.1167/iovs.15-16705.

PMID:
26501236
2.

Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Multicenter Uveitis Steroid Treatment MUST Trial Research Group.

Am J Ophthalmol. 2015 Dec;160(6):1133-1141.e9. doi: 10.1016/j.ajo.2015.09.017. Epub 2015 Sep 18.

PMID:
26386159
3.

Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.

Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group.

Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7.

PMID:
26359188
4.

Relationship between Human Immunodeficiency Virus Neuroretinal Disorder and Vision-Specific Quality of Life among People with AIDS.

Ashraf DC, May KP, Holland GN, Van Natta ML, Wu AW, Thorne JE, Jabs DA; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2015 Dec;122(12):2560-7. doi: 10.1016/j.ophtha.2015.07.037. Epub 2015 Sep 6.

PMID:
26350547
5.
6.

Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE.

Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20.

PMID:
26298715
7.

Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.

Neuschwander-Tetri BA, Van Natta ML, Tonascia J, Brunt EM, Kleiner DE.

Lancet. 2015 Jul 4;386(9988):28-9. doi: 10.1016/S0140-6736(15)61200-4. No abstract available.

PMID:
26169861
8.

Airway Obstruction Worsens in Young Adults with Asthma Who Become Obese.

Strunk RC, Colvin R, Bacharier LB, Fuhlbrigge A, Forno E, Arbelaez AM, Tantisira KG; Childhood Asthma Management Program Research Group.

J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):765-71.e2. doi: 10.1016/j.jaip.2015.05.009. Epub 2015 Jul 9.

PMID:
26164807
9.

Long-term Outcomes of Cytomegalovirus Retinitis in the Era of Modern Antiretroviral Therapy: Results from a United States Cohort.

Jabs DA, Ahuja A, Van Natta ML, Lyon AT, Yeh S, Danis R; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2015 Jul;122(7):1452-63. doi: 10.1016/j.ophtha.2015.02.033. Epub 2015 Apr 17.

PMID:
25892019
10.

Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome.

Jabs DA, Van Natta ML, Sezgin E, Pak JW, Danis R; Studies of the Ocular Complications of AIDS Research Group.

Am J Ophthalmol. 2015 Jun;159(6):1115-1122.e1. doi: 10.1016/j.ajo.2015.01.037. Epub 2015 Mar 11.

PMID:
25769246
11.

Incidence and long-term outcomes of the human immunodefıciency virus neuroretinal disorder in patients with AIDS.

Jabs DA, Drye L, Van Natta ML, Thorne JE, Holland GN; Studies of the Ocular Complications of AIDS Research Group.

Ophthalmology. 2015 Apr;122(4):760-8. doi: 10.1016/j.ophtha.2014.11.009. Epub 2015 Jan 16.

PMID:
25600199
12.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; NASH Clinical Research Network.

Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7. Erratum in: Lancet. 2015 Mar 14;385(9972):946.

PMID:
25468160
13.

The prevalence and incidence of epiretinal membranes in eyes with inactive extramacular CMV retinitis.

Kozak I, Vaidya V, Van Natta ML, Pak JW, May KP, Thorne JE; Studies of the Ocular Complications of AIDS Research Group.

Invest Ophthalmol Vis Sci. 2014 Jun 12;55(7):4304-12. doi: 10.1167/iovs.14-14479.

14.

Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD.

Ophthalmology. 2014 Oct;121(10):1855-62. doi: 10.1016/j.ophtha.2014.04.022. Epub 2014 Jun 5.

15.

Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications.

Howrylak JA, Fuhlbrigge AL, Strunk RC, Zeiger RS, Weiss ST, Raby BA; Childhood Asthma Management Program Research Group.

J Allergy Clin Immunol. 2014 May;133(5):1289-300, 1300.e1-12.

16.

HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.

Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG.

PLoS Pathog. 2014 May 15;10(5):e1004078. doi: 10.1371/journal.ppat.1004078. eCollection 2014 May.

17.

Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.

Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM.

J Infect Dis. 2014 Oct 15;210(8):1228-38. doi: 10.1093/infdis/jiu238. Epub 2014 Apr 21.

18.

Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial.

Parkman HP, Van Natta ML, Abell TL, McCallum RW, Sarosiek I, Nguyen L, Snape WJ, Koch KL, Hasler WL, Farrugia G, Lee L, Unalp-Arida A, Tonascia J, Hamilton F, Pasricha PJ.

JAMA. 2013 Dec 25;310(24):2640-9. doi: 10.1001/jama.2013.282833.

19.

Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.

Branch AD, Drye LT, Van Natta ML, Sezgin E, Fishman SL, Dieterich DT, Meinert CL, Jabs DA.

Clin Infect Dis. 2013 Dec;57(11):1618-25. doi: 10.1093/cid/cit550. Epub 2013 Sep 30.

20.

Correlates of hypertension in patients with AIDS in the era of highly active antiretroviral therapy.

Krauskopf K, Van Natta ML, Danis RP, Gangaputra S, Ackatz L, Addessi A, Federman AD, Branch AD, Meinert CL, Jabs DA; Studies of the Ocular Complications of AIDS Research Group.

J Int Assoc Provid AIDS Care. 2013 Sep-Oct;12(5):325-33.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk